These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 29289479

  • 1. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
    Desai AK, Walters CK, Cope HL, Kazi ZB, DeArmey SM, Kishnani PS.
    Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE, Bjartmar C, Morgan C, Casey R, Charrow J, Clancy JP, Dasouki M, DeArmey S, Nedd K, Nevins M, Peters H, Phillips D, Spigelman Z, Tifft C, Kishnani PS.
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [Abstract] [Full Text] [Related]

  • 3. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M, Zhang L, Quan S.
    Cochrane Database Syst Rev; 2017 Nov 20; 11(11):CD011539. PubMed ID: 29155436
    [Abstract] [Full Text] [Related]

  • 4. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH, Hwu WL, Lee NC.
    Pediatr Neonatol; 2013 Aug 20; 54(4):219-27. PubMed ID: 23632029
    [Abstract] [Full Text] [Related]

  • 5. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
    Rafael Bretón Martínez J, Martínez AC.
    J Neurol Sci; 2015 Nov 15; 358(1-2):459-60. PubMed ID: 26279333
    [No Abstract] [Full Text] [Related]

  • 6. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.
    El-Gharbawy AH, Mackey J, DeArmey S, Westby G, Grinnell SG, Malovrh P, Conway R, Kishnani PS.
    Mol Genet Metab; 2011 Nov 15; 104(1-2):118-22. PubMed ID: 21802969
    [Abstract] [Full Text] [Related]

  • 7. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A, Carlier PG, Carlier RY, Kissel JT, Schoser B, Wenninger S, Pestronk A, Barohn RJ, Dimachkie MM, Goker-Alpan O, Mozaffar T, Pena LD, Simmons Z, Straub V, Guglieri M, Young P, Boentert M, Baudin PY, Wens S, Shafi R, Bjartmar C, Thurberg BL.
    Mol Genet Metab; 2016 Sep 15; 119(1-2):115-23. PubMed ID: 27473031
    [Abstract] [Full Text] [Related]

  • 8. Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.
    Gragnaniello V, Fecarotta S, Pecoraro A, Tarallo A, Catzola A, Spadaro G, Parenti G, Della Casa R.
    Neurol Sci; 2019 Jul 15; 40(7):1453-1455. PubMed ID: 30778879
    [Abstract] [Full Text] [Related]

  • 9. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
    Chen HA, Hsu RH, Fang CY, Desai AK, Lee NC, Hwu WL, Tsai FJ, Kishnani PS, Chien YH.
    Front Immunol; 2024 Jul 15; 15():1336599. PubMed ID: 38715621
    [Abstract] [Full Text] [Related]

  • 10. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
    de Vries JM, van der Beek NA, Kroos MA, Ozkan L, van Doorn PA, Richards SM, Sung CC, Brugma JD, Zandbergen AA, van der Ploeg AT, Reuser AJ.
    Mol Genet Metab; 2010 Dec 15; 101(4):338-45. PubMed ID: 20826098
    [Abstract] [Full Text] [Related]

  • 11. Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy.
    McIntosh PT, Hobson-Webb LD, Kazi ZB, Prater SN, Banugaria SG, Austin S, Wang R, Enterline DS, Frush DP, Kishnani PS.
    Mol Genet Metab; 2018 Feb 15; 123(2):85-91. PubMed ID: 29050825
    [Abstract] [Full Text] [Related]

  • 12. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
    Löscher WN, Huemer M, Stulnig TM, Simschitz P, Iglseder S, Eggers C, Moser H, Möslinger D, Freilinger M, Lagler F, Grinzinger S, Reichhardt M, Bittner RE, Schmidt WM, Lex U, Brunner-Krainz M, Quasthoff S, Wanschitz JV.
    J Neurol; 2018 Jan 15; 265(1):159-164. PubMed ID: 29181627
    [Abstract] [Full Text] [Related]

  • 13. Early higher dosage of alglucosidase alpha in classic Pompe disease.
    Spada M, Pagliardini V, Ricci F, Biamino E, Mongini T, Porta F.
    J Pediatr Endocrinol Metab; 2018 Dec 19; 31(12):1343-1347. PubMed ID: 30433875
    [Abstract] [Full Text] [Related]

  • 14. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI, Samjoo IA, Hettinga BP, Koeberl DD, Zhang H, Hawke TJ, Nissar AA, Ali T, Brandt L, Ansari MU, Hazari H, Patel N, Amon J, Tarnopolsky MA.
    Mol Genet Metab; 2012 Nov 19; 107(3):469-79. PubMed ID: 23041258
    [Abstract] [Full Text] [Related]

  • 15. Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study.
    Ditters IAM, van der Beek NAME, Brusse E, van der Ploeg AT, van den Hout JMP, Huidekoper HH.
    Orphanet J Rare Dis; 2023 May 08; 18(1):108. PubMed ID: 37158969
    [Abstract] [Full Text] [Related]

  • 16. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G, Krase A, Papadimas G, Papadopoulos C, Kavouras SA, Manta P.
    Mol Genet Metab; 2012 Dec 08; 107(4):669-73. PubMed ID: 23146291
    [Abstract] [Full Text] [Related]

  • 17. Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions.
    Ditters IAM, van Kooten HA, van der Beek NAME, Hardon JF, Ismailova G, Brusse E, Kruijshaar ME, van der Ploeg AT, van den Hout JMP, Huidekoper HH.
    BioDrugs; 2023 Sep 08; 37(5):685-698. PubMed ID: 37326923
    [Abstract] [Full Text] [Related]

  • 18. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
    Kobayashi H, Shimada Y, Ikegami M, Kawai T, Sakurai K, Urashima T, Ijima M, Fujiwara M, Kaneshiro E, Ohashi T, Eto Y, Ishigaki K, Osawa M, Kyosen SO, Ida H.
    Mol Genet Metab; 2010 May 08; 100(1):14-9. PubMed ID: 20202878
    [Abstract] [Full Text] [Related]

  • 19. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec 08; 16(92):240-1. PubMed ID: 18092404
    [Abstract] [Full Text] [Related]

  • 20. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry.
    Lessard LER, Tard C, Salort-Campana E, Sacconi S, Béhin A, Bassez G, Orlikowski D, Merle P, Nollet S, Gallay L, Bérard F, Robinson P, Bouhour F, Laforêt P.
    Mol Genet Metab; 2023 Jul 08; 139(3):107611. PubMed ID: 37285781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.